About Third Rock Ventures
Third Rock Ventures is a venture capital firm founded in 2007. It is primarily based out of Boston, United States. As of Sep 2026, Third Rock Ventures is an active investor, having invested in 76 companies, with 2 new investments in the last 12 months. It primarily invests in Series A round in United States based startups. Its investments are spread across a wide range of sectors from Life Sciences to High Tech and HealthTech. Most recently it participated in the $***** Post IPO round of Lisata Overall, Third Rock Ventures portfolio has seen 20 IPOs and 27 acquisitions including key companies like Rhythm Pharmaceuticals, Nurix Therapeutics and Blueprint Medicines. A lot of funds co-invest with Third Rock Ventures, with names like Google Ventures sharing a substantial percentage of its portfolio. Third Rock Ventures has team of 47 people including 10 partners.Key Metrics
Team Members
Portfolio Count
Portfolio Sectors
Portfolio Locations
Rounds of Entry
Series A, Series B & 4 more
Portfolio IPOs
Portfolio Acquisitions
Portfolio Soonicorns
Deals in last 12 months
Third Rock Ventures' List of Top Investments
Third Rock Ventures has a portfolio of 76 companies. Their most notable investments are in Goldfinch and Edimer Pharma.Their portfolio spans across United States, France and Germany. They have invested in Life Sciences, High Tech, HealthTech and 3 other sectors, across stages such as Series A, Series B and 4 more. Here is the list of top investments by Third Rock Ventures:Developer of peptide therapeutics for the treatment of rare genetic deficiencies. It offers a lead peptide product candidate setmelanotide which is a potent, first-in-class melanocortin-4 receptor (MC4R) agonist for the treatment of Prader-Willi syndrome (PWS) and pro-opiomelanocortin deficiency obesity.
Key facts about Rhythm Pharmaceuticals
- Founded Year: 2010
- Location: Boston (United States)
- Annual Revenue: $100M - $500M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $84M
- Employee Count: 510 as on Sep 30, 2026
- Investors: Venrock, Foresite Capital and 9 Others
- Latest Funding Round: Post IPO, Apr 01, 2024, $*****
- Highlight: Public
Nurix provides the platform for controlling the body natural protein level and regulation. It offers its candidate ubiquitin E3 ligases which helps in treating a broad range of disease by the breakdown of protein in the cell. The many pipelines if the company includes, CBL -B, BTX which are at the preclinical and other prior stages of approval. It also focus in developing the drug for treatment of cancer, small molecule, immunoncology agents and others.
Key facts about Nurix Therapeutics
- Founded Year: 2009
- Location: San Francisco (United States)
- Annual Revenue: $50M - $100M as on Nov 30, 2025
- Stage: Public
- Total Funding till date: $173M
- Employee Count: 381 as on Aug 31, 2026
- Investors: Bain Capital Life Sciences, Foresite Capital and 9 Others
- Latest Funding Round: Series B, Mar 26, 2020, $*****
- Highlight: Public
Developer of selective kinase inhibitors for patients with genomically defined cancers. Their approach is rooted in a deep understanding of the genetic blueprint of cancer and other diseases driven by the abnormal activation of kinases. Their ability to identify novel drivers of disease, coupled with our proprietary library of novel and diverse chemical compounds, uniquely enables us to craft kinase therapies against new and difficult-to-drug targets.
Key facts about Blueprint Medicines
- Founded Year: 2008
- Location: Cambridge (United States)
- Annual Revenue: $500M - $1B as on Dec 31, 2024
- Last Known Valuation: $*****
- Stage: Acquired
- Total Funding till date: $115M
- Employee Count: 674 as on Sep 30, 2026
- Investors: BVF Partners, Foresite Capital and 20 Others
- Latest Funding Round: Post IPO, Jun 30, 2022, $*****
- Highlight: Acquired
Tango Therapeutics is a biotech company developing novel drugs for the treatment of cancer. The company uses DNA sequencing and CRISPR-based screening to identify targets for specific subgroups of cancer patients. The company is discovering novel targets using synthetic lethality, where the cancer-causing alteration in a tumour suppressor gene creates a vulnerability that leads to the destruction of the tumour cell.
Key facts about Tango Therapeutics
- Founded Year: 2017
- Location: Cambridge (United States)
- Annual Revenue: $50M - $100M as on Dec 31, 2025
- Stage: Public
- Total Funding till date: $165M
- Employee Count: 181 as on Sep 30, 2026
- Investors: Bain Capital Life Sciences, Boxer Capital and 8 Others
- Latest Funding Round: Post IPO, Oct 24, 2025, $*****
- Highlight: Public
5. Insitro
Developer of machine learning platform for drug discovery and development. The platform integrates cellular data with human clinical data to redefine disease. It aims to accelerate the development of new medicines. The platform identifies therapeutic insights and interventions across a wide spectrum of diseases. The company is building a pipeline of therapeutic programs in metabolism, oncology, and neuroscience.
Key facts about Insitro
- Founded Year: 2018
- Location: San Francisco (United States)
- Valuation: $*****
- Stage: Series C
- Total Funding till date: $643M
- Employee Count: 257 as on Aug 31, 2026
- Investors: ADS Ventures, Foresite Capital and 18 Others
- Latest Funding Round: Series C, Mar 15, 2021, $*****
- Highlight: Editors' Pick
Third Rock Ventures' Year-on-Year Investment Trends
Third Rock Ventures has invested in 76 companies over the last 18 years, with an average of 3 new investments annually in the last 10 years. In 2025, it made 5 investments, while as of Sep 2026, it has made 3 investments in this year. Its most recent first time investment was in Lisata and most recent follow-on round was in Flare Therapeutics.Year | No. of Investments | ||
|---|---|---|---|
1st Round | Follow-on | Total | |
2026 (YTD) | 1 | 2 | 3 |
2025 | 2 | 3 | 5 |
2024 | 4 | 3 | 7 |
2023 | 5 | 3 | 8 |
2022 | 2 | 3 | 5 |
2021 | 3 | 4 | 7 |
2020 | 3 | 5 | 8 |
2019 | 4 | 2 | 6 |
2018 | 4 | 3 | 7 |
2017 | 3 | 4 | 7 |
Third Rock Ventures' Investments by Stage
Third Rock Ventures is primarily an Early Stage Investor investor majorly investing in Series A (58) rounds where average round size is $3.31B, Series B (6) rounds where average round size is $178M and Series C (3) rounds where average round size is $370M.Stage of entry | No. of Investments |
|---|---|
Series A | 58 |
Series B | 6 |
Series C | 3 |
Series D | 2 |
Post IPO | 1 |
Others | 1 |
Note: We have considered here, only first round of investments
Third Rock Ventures' Investments by Sector
Third Rock Ventures has a diverse portfolio, with companies operating in the Life Sciences, High Tech, Enterprise Applications, HealthTech and Artificial Intelligence - Industry Applications. Notably, it has invested in 72 Tech companies, 69 Enterprise (B2B) companies, 11 Software companies and at least 5 companies focusing on Consumer (B2C).Sector | No. of Investments |
|---|---|
Life Sciences | 71 |
High Tech | 16 |
Enterprise Applications | 6 |
HealthTech | 4 |
Artificial Intelligence - Industry Applications | 2 |
Others | 6 |
Note: We have considered here, only first round of investments
Third Rock Ventures' Investments by Geography
Third Rock Ventures has made most investments in United States (70), followed by France where it has made 1 investment.Country | No. of Investments |
|---|---|
United States | 70 |
France | 1 |
Note: We have considered here, only first round of investments
Third Rock Ventures' recent investments
Third Rock Ventures has made 3 investments in 2026 so far. Lisata and Flare Therapeutics are the latest among them.Here are the most recent investments by Third Rock Ventures:
Filter this listDate | Company | Location | Round Details | Round Amount | Co-Investors |
|---|---|---|---|---|---|
Sep 18, 2026 | United States | Post IPO | 1999 | [+11] | |
Jun 30, 2026 | United States | Series C | 1726 | [+9] | |
Apr 10, 2026 | United States | Series C | 5479 | ||
Dec 18, 2025 | France | Series A | 4775 | [+4] | |
Nov 04, 2025 | United States | Series A | 9538 |
IPOs and Publicly Listed companies in Third Rock Ventures' Portfolio
20 of Third Rock Ventures' portfolio companies have become public. Seaport Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ), in May 2026 at marketcap of $912M and Maze Therapeutics got listed on the National Association of Securities Dealers Automated Quotations (NASDAQ) at marketcap of $700M.Here are Third Rock Ventures' portfolio companies that went public:
Company | IPO Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
May 01, 2026 | Apr 09, 2024 | Series A | 3194 | |
Jan 31, 2025 | Mar 01, 2019 | Series C | 7664 | |
Oct 25, 2024 | Jan 27, 2022 | Series A | 9582 | |
Jun 07, 2024 | Mar 07, 2023 | Series A | 6846 | |
Sep 04, 2020 | Mar 30, 2017 | Series A | 9462 |
Acquired companies in Third Rock Ventures' Portfolio
27 companies from Third Rock Ventures' portfolio have been acquired. The most recent acquisition was Marea Therapeutics in Sep 2026 by Lisata for $*****.Here are Third Rock Ventures' portfolio companies that got acquired most recently:
Company | Acquisition Date | First Invested on | First Round of Investment | Round Size |
|---|---|---|---|---|
Sep 18, 2026 | - | - | 1945 | |
Aug 31, 2026 | Apr 09, 2025 | Series A | 7539 | |
May 03, 2026 | Sep 09, 2024 | Series D | 8865 | |
Jan 21, 2026 | Sep 18, 2026 | Post IPO | 4144 | |
Dec 03, 2025 | May 11, 2011 | Series A | 3046 |
Team profile of Third Rock Ventures
Third Rock Ventures has a team of 47 members including 10 Partners, 14 Venture Partners and 5 Principals located in United States and Canada. Third Rock Ventures' team sits on the board of 1 company.Here is a list of top team members in Third Rock Ventures:
Name | Designation | Location | Board Memberships | Contact Details |
|---|---|---|---|---|
Partner | Boston | - | ||
Partner | Boston | - | - | |
Partner | Waban | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Partner | Palo Alto | - | - | |
Partner | Boston | - | - | |
Partner | - | - | - | |
Partner | Milton | - | - | |
Partner | Clinton | - | - |
Co-investors of Third Rock Ventures
Over the past 18 years, 319 investors have co-invested in Third Rock Ventures's portfolio companies. This includes funds and angels.
- Invested before Third Rock Ventures: HHS, New Enterprise Associates and 15 others have invested in rounds before Third Rock Ventures. There are 3 companies where HHS has invested before Third Rock Ventures and 1 company where New Enterprise Associates has invested before Third Rock Ventures.
- Top Co-investors of Third Rock Ventures: 117 investors entered a company along with Third Rock Ventures. These include investors like Google Ventures (9 companies).
- Invested after Third Rock Ventures: A total of 185 investors have invested in Third Rock Ventures's portfolio after their investments. Top Investors include Casdin Capital (18 companies), Wellington (11 companies) and RA Capital Management (11 companies).
Recent News related to Third Rock Ventures
•
Perpetual Medicines and Third Rock Ventures Deliver Development Candidate in Under 18 Months Using AI and Computational PhysicsBusiness Wire•Jun 09, 2026•Perpetual Medicines, Third Rock Ventures
•
Terremoto Biosciences Raises $108M in Series C FundingFinSMEs•Apr 15, 2026•Terremoto, RA Capital Management, Deep Track Capital, Cormorant-asset and 4 others
•
Syremis Therapeutics Raises $165M in Series A FinancingFinSMEs•Dec 19, 2025•Pictet Group, QVT Family Office, Bain Capital Life Sciences, Dexcel and 3 others
•
Stealth Third Rock Ventures Backed Company Selects Parse Biosciences GigaLab to Build Largest TCR Atlas for Common Autoimmune DiseaseBusiness Wire•Nov 12, 2025•Parse Biosciences, Third Rock Ventures
•
Azalea Therapeutics Launches with $82 Million Financing to Redefine Precision Genomic Medicines by Engineering Cells Directly Inside Each PatientFinancial Post•Nov 04, 2025•Azalea Therapeutics, Sozo Ventures, RA Capital Management, Third Rock Ventures and 1 other
•
T.Rx Capital closes $77M inaugural fundEndpoints•Sep 18, 2025•T.Rx Capital, Third Rock Ventures, Arch Venture Partners, Polaris Partners and 1 other
•
Artbio secures $132M funding as its alpha radioligand program enters clinical trialsEndpoints•Jul 29, 2025•Parabilis Medicines, ARTBIO, 3B Pharmaceuticals, Novartis and 9 others
•
Corvia Medical secures $55M funding to complete trial and pursue FDA approval for Atrial Shuntintelligence360•Jun 30, 2025•Corvia Medical, Lumira Ventures, Accelmed, General Catalyst and 1 other
•
Corvia Medical closes $55M funding round for confirmatory trial & FDA approval of Corvia Atrial ShuntCNW•Jun 17, 2025•Corvia Medical, Third Rock Ventures, General Catalyst
•
Maze Therapeutics raises $115m to advance kidney disease candidatesPharmaceutical Technology•Dec 04, 2024•Maze Therapeutics, Deep Track Capital, Frazier Life Sciences, Logos and 7 others
